Literature DB >> 21120186

JAK2 V617F and the evolving paradigm of polycythemia vera.

Robert T Means1.   

Abstract

Polycythemia vera (PV) was first described nearly 120 years ago. In the subsequent century, the clinical syndrome of PV, its natural history, its treatment, and many critical pathogenetic features of the disease were characterized. The discovery of the Janus-associated kinase - 2 mutation JAK2 V617F and the characterization of its role in myeloproliferative neoplasms have substantially changed the diagnostic paradigm for PV, and have potential to lead to new therapy and new pathogenetic insights.

Entities:  

Keywords:  Diagnosis; JAK2; Myeloproliferative neoplasms; Polycythemia vera

Year:  2010        PMID： 21120186      PMCID： PMC2983020          DOI： 10.5045/kjh.2010.45.2.90

Source DB:  PubMed          Journal:  Korean J Hematol        ISSN： 1738-7949


  41 in total

1.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Authors:  Betty Cheung; Deepti Radia; Panagiotis Pantelidis; Ghasem Yadegarfar; Claire Harrison
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Authors:  A Pardanani; J Hood; T Lasho; R L Levine; M B Martin; G Noronha; C Finke; C C Mak; R Mesa; H Zhu; R Soll; D G Gilliland; A Tefferi
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

3.  Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

Authors:  A Pardanani; T L Lasho; C Finke; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2007-06-28       Impact factor: 11.528

Review 4.  The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Authors:  Jan J Michiels; Hendrik De Raeve; Zwi Berneman; Dirk Van Bockstaele; Konnie Hebeda; King Lam; Wilfried Schroyens
Journal:  Semin Thromb Hemost       Date:  2006-06       Impact factor: 4.180

5.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera.

Authors:  A R Moliterno; J L Spivak
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

8.  Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Authors:  Shu Xing; Tina Ho Wanting; Wanming Zhao; Junfeng Ma; Shaofeng Wang; Xuesong Xu; Qingshan Li; Xueqi Fu; Mingjiang Xu; Zhizhuang Joe Zhao
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

9.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

10.  The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.

Authors:  Shireen Sirhan; Terra L Lasho; Curtis A Hanson; Ruben A Mesa; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2008-05       Impact factor: 10.047
View more
  2 in total

Review 1.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

Review 2.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.